🚀 VC round data is live in beta, check it out!
Takara Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Takara Bio and similar public comparables like Biotest, SunOpta, Gujarat State Fertilizers, Personalis and more.
Takara Bio Overview
About Takara Bio
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
Founded
2002
HQ
Employees
1.5K
Website
Financials (LTM)
EV
$802M
Takara Bio Financials
Takara Bio reported last 12-month revenue of $313M.
In the same LTM period, Takara Bio generated $30M in net income.
Revenue (LTM)
Takara Bio P&L
In the most recent fiscal year, Takara Bio reported revenue of $308M and EBITDA of $45M.
Takara Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $313M | XXX | $308M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $164M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBITDA | — | XXX | $45M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $30M | XXX | $7M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 2% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Takara Bio Stock Performance
Takara Bio has current market cap of $864M, and enterprise value of $802M.
Market Cap Evolution
Takara Bio's stock price is $7.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $802M | $864M | -0.2% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTakara Bio Valuation Multiples
Takara Bio trades at 2.6x EV/Revenue multiple, and 17.6x EV/EBITDA.
EV / Revenue (LTM)
Takara Bio Financial Valuation Multiples
As of April 18, 2026, Takara Bio has market cap of $864M and EV of $802M.
Equity research analysts estimate Takara Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Takara Bio has a P/E ratio of 28.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $864M | XXX | $864M | XXX | XXX | XXX |
| EV (current) | $802M | XXX | $802M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 17.6x | XXX | XXX | XXX |
| EV/EBIT | 20.2x | XXX | 51.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.9x | XXX | XXX | XXX |
| P/E | 28.9x | XXX | 121.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (28.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Takara Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Takara Bio Margins & Growth Rates
Takara Bio's revenue in the last fiscal year grew by 2%.
Takara Bio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Takara Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (5%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Takara Bio Public Comps
See public comps and valuation multiples for other Bioindustrials and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Takara Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Biotest | XXX | XXX | XXX | XXX | XXX | XXX |
| SunOpta | XXX | XXX | XXX | XXX | XXX | XXX |
| Gujarat State Fertilizers | XXX | XXX | XXX | XXX | XXX | XXX |
| Personalis | XXX | XXX | XXX | XXX | XXX | XXX |
| Anhui Huaheng | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Takara Bio M&A Activity
Takara Bio acquired XXX companies to date.
Last acquisition by Takara Bio was on XXXXXXXX, XXXXX. Takara Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Takara Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTakara Bio Investment Activity
Takara Bio invested in XXX companies to date.
Takara Bio made its latest investment on XXXXXXXX, XXXXX. Takara Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Takara Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Takara Bio
| When was Takara Bio founded? | Takara Bio was founded in 2002. |
| Where is Takara Bio headquartered? | Takara Bio is headquartered in Japan. |
| How many employees does Takara Bio have? | As of today, Takara Bio has over 1K employees. |
| Who is the CEO of Takara Bio? | Takara Bio's CEO is Koichi Nakao. |
| Is Takara Bio publicly listed? | Yes, Takara Bio is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Takara Bio? | Takara Bio trades under 4974 ticker. |
| When did Takara Bio go public? | Takara Bio went public in 2004. |
| Who are competitors of Takara Bio? | Takara Bio main competitors are Biotest, SunOpta, Gujarat State Fertilizers, Personalis. |
| What is the current market cap of Takara Bio? | Takara Bio's current market cap is $864M. |
| What is the current revenue of Takara Bio? | Takara Bio's last 12 months revenue is $313M. |
| What is the current revenue growth of Takara Bio? | Takara Bio revenue growth (vs. last FY) is 2%. |
| What is the current EV/Revenue multiple of Takara Bio? | Current revenue multiple of Takara Bio is 2.6x. |
| Is Takara Bio profitable? | Yes, Takara Bio is net-income-positive (as of the last 12 months). |
| What is the current net income of Takara Bio? | Takara Bio's last 12 months net income is $30M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.